2. Search Result
Search Result
Results for "

3CLPRO

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

2

Natural
Products

4

Recombinant Proteins

13

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W760546
    SARS-CoV-2 3CLpro-IN-15

    		SARS-CoV Virus Protease Infection
    SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .
    SARS-CoV-2 <em>3CLpro</em>-IN-15
  • HY-144833
    SARS-CoV-2 3CLpro-IN-1

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL pro. 3CL pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .
    SARS-CoV-2 <em>3CLpro</em>-IN-1
  • HY-155979
    SARS-CoV-2 3CLpro-IN-16

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro .
    SARS-CoV-2 <em>3CLpro</em>-IN-16
  • HY-147804
    SARS-CoV-2 3CLpro-IN-3

    		SARS-CoV Bacterial Fungal Infection
    SARS-CoV-2 3CLpro-IN-3 (Compound 3d) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .
    SARS-CoV-2 <em>3CLpro</em>-IN-<em>3</em>
  • HY-147805
    SARS-CoV-2 3CLpro-IN-4

    		SARS-CoV Bacterial Fungal Infection
    SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .
    SARS-CoV-2 <em>3CLpro</em>-IN-4
  • HY-155980
    SARS-CoV-2 3CLpro-IN-17

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC50s: 0.322 μM) .
    SARS-CoV-2 <em>3CLpro</em>-IN-17
  • HY-151535
    SARS-CoV-2 3CLpro-IN-5

    		SARS-CoV Infection Inflammation/Immunology
    SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CL pro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL pro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 <em>3CLpro</em>-IN-5
  • HY-155540
    SARS-CoV-2 3CLpro-IN-14

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active SARS-CoV-2 3CLpro inhibitor. SARS-CoV-2 3CLpro-IN-14 shows significant anti-SARS-CoV-2 activity (EC50 = 0.18 μM) and low cytotoxicity (CC50 > 50 μM) in Vero E6 cells .
    SARS-CoV-2 <em>3CLpro</em>-IN-14
  • HY-155187
    SARS-CoV-2 3CLpro-IN-20

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.43 μM, Ki: ?0.33?μM) .
    SARS-CoV-2 <em>3CLpro</em>-IN-20
  • HY-155981
    SARS-CoV-2 3CLpro-IN-18

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.478 μM). SARS-CoV-2 3CLpro-IN-18 inhibits SARS-CoV-2 in Vero E6 cells (EC50= 2.499 μM) with low cytotoxicity (CC50 > 200 μM) .
    SARS-CoV-2 <em>3CLpro</em>-IN-18
  • HY-146998
    SARS-CoV-2 3CLpro-IN-2

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases .
    SARS-CoV-2 <em>3CLpro</em>-IN-2
  • HY-149264
    SARS-CoV-2 3CLpro-IN-13

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-13 is a potent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-13 shows anti-coronavirus activity .
    SARS-CoV-2 <em>3CLpro</em>-IN-13
  • HY-152005
    SARS-CoV-2 3CLpro-IN-6

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL pro with an IC50 value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 <em>3CLpro</em>-IN-6
  • HY-157477
    SARS-CoV-2 3CLpro-IN-22

    		SARS-CoV Cathepsin Infection
    SARS-CoV-2 3CLpro-IN-22 (Compound 17) is a cathepsin L (CTSL ) inhibitor with an IC50 value of 32.5 nM. SARS-CoV-2 3CLpro-IN-22 can be used for the study of SARS-CoV-2 virus .
    SARS-CoV-2 <em>3CLpro</em>-IN-22
  • HY-155186
    SARS-CoV-2 3CLpro-IN-19

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC50s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC50 values between 30-69 nM .
    SARS-CoV-2 <em>3CLpro</em>-IN-19
  • HY-157966
    SARS-CoV-2 3CLpro-IN-23

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-23 (Compound Cd3) is a compound that can be isolated from Citrus depressa. SARS-CoV-2 3CLpro-IN-23 has good inhibitory activity to the SARS-CoV-2 spike protein, with KD of 0.79 μM. SARS-CoV-2 3CLpro-IN-23 can bind to key amino acid residue, disrupting the formation of the spike protein and h-ACE2 complex .
    SARS-CoV-2 <em>3CLpro</em>-IN-23
  • HY-156007
    SARS-CoV-2 3CLpro-IN-21

    		SARS-CoV Virus Protease Infection
    SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CL pro with an IC50 of 0.03 μM. SARS-CoV-2 3CLpro-IN-21 also inhibits SARS-CoV-13CL pro with an IC50 of 0.12μM .
    SARS-CoV-2 <em>3CLpro</em>-IN-21
  • HY-144260
    3CPLro-IN-1

    		SARS-CoV Infection
    3CPLro-IN-1 (compound A17) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC50 of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .
    <em>3</em>CPLro-IN-1
  • HY-152009
    SARS-CoV-2 3CLpro-IN-7

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 1.4 µM .
    SARS-CoV-2 <em>3CLpro</em>-IN-7
  • HY-144263
    3CPLro-IN-2

    		SARS-CoV Infection
    3CPLro-IN-2 (compound C1) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC50 and Ki of 1.55 and 6.09 μM, respectively. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .
    <em>3</em>CPLro-IN-2
  • HY-150691
    SARS 3CLpro-IN-1

    		SARS-CoV Cancer
    SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC50 value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole .
    SARS <em>3CLpro</em>-IN-1
  • HY-144747
    Hydroxyethylamine

    		SARS-CoV Infection
    Hydroxyethylamine (Compd VII) is a SARS-CoV-2 3CLpro inhibitor with an IC50 of ~10 μM in the spread assay. Hydroxyethylamine has potent antiviral activities .
    Hydroxyethylamine
  • HY-N12384
    (25S)-Antcin B

    		SARS-CoV Infection
    Antcin-B is a potent inhibitor of 3CLPro with high affinity. Antcin-B can be used in study SARS-CoV-2 .
    (25S)-Antcin B
  • HY-145276
    SARS-CoV-2-IN-10

    		SARS-CoV Infection
    SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    SARS-CoV-2-IN-10
  • HY-145277
    SARS-CoV-2-IN-11

    		SARS-CoV Infection
    SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    SARS-CoV-2-IN-11
  • HY-137954
    GRL-0496

    		SARS-CoV Infection
    GRL-0496 is a potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitor, with an IC50 of 30 nM in both enzyme inhibitory and antiviral assays. GRL-0496 shows SARS-CoV antiviral activity, with an EC50 of 6.9 μM .
    GRL-0496
  • HY-N8306
    Isojacareubin

    		Bacterial PKC Apoptosis SARS-CoV Cancer
    Isojacareubin can be isolated from Hypericum japonicum. Isojacareubin covalently inhibits SARS-CoV-2 3CLpro. Isojacareubin also has anti-helicobacter activity. Isojacareubin inhibits PKC, and suppresses hepatocellular carcinoma metastasis and induces apoptosis [3].
    Isojacareubin
  • HY-161177
    PROTAC KRAS G12D degrader 2

    		PROTACs Ras Infection
    PROTAC KRAS G12D degrades SARS-CoV-2, 3-curd trypsin-like protease (3CLPro). Protac KRAS G12D degrades SARS-CoV-2, 3-curd trypsin-like protease (3CLPRO). The PROTAC molecule is designed by partially coupling a GC-376-based dipeptidyl 3CLPro ligand with pomadomide via a piperazine-piperidine linker .
    PROTAC KRAS G12D degrader 2
  • HY-149535
    WU-04

    		SARS-CoV Infection
    WU-04 is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein. WU-04 has high inhibitory effect on the 3CLpro protein of 6 SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Lambda and Omicron) and 2 coronaviruses (SARS-CoV and MERS-CoV) .
    WU-04
  • HY-138078
    Lufotrelvir
    1 Publications Verification

    PF-07304814

    		 SARS-CoV Infection
    Lufotrelvir (PF-07304814), a phosphate proagent of PF-00835231, acts as a potent 3CLpro protease (Mpro) inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174nM. Lufotrelvir is promising single antiviral agent and also can be used for the research of combination with other antivirals that target other critical stages of the coronavirus life cycle.
    Lufotrelvir
  • HY-136259
    ML188
    4 Publications Verification

    		 SARS-CoV Virus Protease Infection
    ML188, a first in class probe, is a selective non-covalent SARS-CoV 3CLpro inhibitor with an IC50 of 1.5 μM. Antiviral activity .
    ML188
  • HY-132886
    SARS-CoV-2-IN-6

    		SARS-CoV Infection
    SARS-CoV-2-IN-6 is a SARS-CoV-2 3CLpro inhibitor that shows the most potent enzyme inhibitory IC50 value of 73 nM.
    SARS-CoV-2-IN-6
  • HY-162236
    SARS-CoV-2-IN-80

    		SARS-CoV Infection
    SARS-CoV-2-IN-80 (compound 13) is a potent SARS-CoV-2 3CLpro inhibitor with an IC50 value of 0.964 µM .
    SARS-CoV-2-IN-80
  • HY-17007S
    Saquinavir-d9

    		Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Infection Cancer
    Saquinavir-d9 is the deuterium labeled Saquinavir. Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.36 μM[1][2].
    Saquinavir-d9
  • HY-90001S
    Ritonavir-d6

    ABT 538-d6; RTV-d6

    		 HIV Protease HIV SARS-CoV Apoptosis Infection
    Ritonavir-d6 is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM[1][2].
    Ritonavir-d6
  • HY-90001S1
    Ritonavir-13C,d3

    ABT 538-13C,d3; RTV-13C,d3

    		 HIV Protease HIV SARS-CoV Apoptosis Infection
    Ritonavir- 13C,d3 is the 13C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.
    Ritonavir-13C,d<em>3</em>
  • HY-17430S1
    Amprenavir-d4-1

    VX-478-d4-1

    		 Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Infection Cancer
    Amprenavir-d4-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.
    Amprenavir-d4-1
  • HY-17430S
    Amprenavir-d4

    		Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Infection Cancer
    Amprenavir-d4 is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM[1][2].
    Amprenavir-d4
  • HY-162313
    NIP-22c

    		SARS-CoV Infection
    NIP-22c is a novel coronavirus 3CLpro inhibitor. The EC50 for Verona, Calu3, Caco2 and HBTEC-ALI were 4.6, 1.1, 0.1 and 0.6 μM, respectively. NIP-22c has antiviral activity .
    NIP-22c
  • HY-15602S
    Ledipasvir-d6

    GS-5885-d6

    		 HCV SARS-CoV Infection
    Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].
    Ledipasvir-d6
  • HY-90001S3
    rel-Ritonavir-d6

    rel-ABT 538-d6; rel-RTV-d6

    		 Isotope-Labeled Compounds Others
    rel-Ritonavir-d6 (rel-ABT 538-d6; rel-RTV-d6) is the deuterium labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM .
    rel-Ritonavir-d6
  • HY-10237S
    Boceprevir-d9

    EBP 520-d9; SCH 503034-d9

    		 Isotope-Labeled Compounds HCV Protease HCV SARS-CoV Infection
    Boceprevir-d9 is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].
    Boceprevir-d9
  • HY-136606
    SARS-CoV MPro-IN-1

    		SARS-CoV Infection
    SARS-CoV MPro-IN-1 is a SARS-CoV-2 3CLpro covalent inhibitor, with an IC50 of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC50 of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research .
    SARS-CoV MPro-IN-1
  • HY-17367S3
    Atazanavir-d5

    		Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Infection Cancer
    Atazanavir-d5 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].
    Atazanavir-d5
  • HY-17367S2
    Atazanavir-d9

    BMS-232632-d9

    		 Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Infection Cancer
    Atazanavir-d9 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].
    Atazanavir-d9
  • HY-10235S
    Telaprevir-d4

    VX-950-d4

    		 Isotope-Labeled Compounds HCV Protease HCV SARS-CoV Infection
    Telaprevir-d4 is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].
    Telaprevir-d4
  • HY-17367S4
    Atazanavir-d6

    BMS-232632-d6

    		 Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Infection Cancer
    Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].
    Atazanavir-d6
  • HY-14588S1
    Lopinavir-d8

    		HIV HIV Protease SARS-CoV Infection
    Lopinavir-d8 (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM[3].
    Lopinavir-d8
  • HY-18219
    Walrycin B
    1 Publications Verification

    		 SARS-CoV Bacterial Antibiotic Infection Inflammation/Immunology
    Walrycin B, an analogue of toxoflavin, is a potent SARS-CoV-2 3CL pro inhibitor with an IC50 of 0.26 μM. Walrycin B is a WalR response regulator inhibitor. Walrycin B has potent activity of inhibiting bacteria growth .
    Walrycin B
  • HY-15602C
    Ledipasvir hydrochloride

    GS-5885 hydrochloride

    		 HCV SARS-CoV Infection
    Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM [3].
    Ledipasvir hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: